Pharmaceutical Services

WuXi AppTec (603259.SH/2359.HK) announced its first interim dividend, distributing RMB 1.03 billion to shareholders, demonstrating financial strength and commitment to shareholder value. Year-to-date, the company has distributed RMB 4.88 billion in dividends and repurchased shares, totaling RMB 6.88 billion in shareholder returns – over 70% of its 2024 net profit. This reflects confidence in future growth and strong cash flow. WuXi AppTec’s CRDMO platform is driven by increasing demand for R&D and manufacturing services, positioning it as a key partner for global pharmaceutical and biotech companies.